Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Active, not recruiting · Phase 2 · NCT05994235
Conditions: Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $2.1M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 23
About the trial
- Sponsor
- Weill Medical College of Cornell University (with Epizyme, Inc., Genentech, Inc.)
- Tested
- Mosunetuzumab (drug), Tazemetostat Pill (drug)
- Dates
- Started 2023-11-01; completion 2033-10
- Results posted
- Not yet
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypothesize that tazemetostat with mosunetuzumab has the potential to increase the efficacy of the product without compromising the safety. Tazemetostat is a drug that inhibits EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system's ability to fight it. Tazemetostat is FDA-approved in previously treated follicular lymphoma a…
From ClinicalTrials.gov, last updated 2026-04-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $2.1M in research payments for this study in 2025 (6 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- New York-Presbyterian Hospital, NY $1.9M
- Weill Cornell Medicine $207,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.